Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal contract development and manufacturing partners, today announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025. With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Or

Read more...

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos Rovi, S.A., a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mR

Read more...

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control™ product platform to discover and develop novel therapeutics against a transcription factor target believed to be relevant to a broad range of

Read more...

Regeneron Pharmaceuticals, Inc. announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2. REGN-COV2 is Re

Read more...

Nephron Pharmaceuticals Corporation, one of the fastest-growing pharmaceuticals companies in the country, today announced a new collaboration with Methapharm. As a part of this collaboration, Nephron will produce kits of methacholine chloride sterile inhalation solution in ready-to-administer concentrations for bronchoprovocation challenge testing, when diagnosing respiratory illnesses, such as asthma. "Methapharm will be a fantastic partner," said Nephron CEO Lo

Read more...

Dragonfly Therapeutics announces new research collaboration with Bristol Myers Squibb to develop new therapeutic candidates for multiple sclerosis and neuro-inflammation targets Dragonfly grows beyond its existing collaboration with Bristol Myers Squibb in the oncology and autoimmune disease sector to develop candidate drugs against multiple targets using its proprietary platform in new therapeutic areas WALTHAM, Massachusetts, July 6, 2020 / PRNewswire / - Dragonfly Thera

Read more...

CSL Behring , world leader in biotherapeutics, announced today that the European Medicines Agency (EMA) has approved the new summary of product characteristics, which includes information on new extended dosing options for IDELVION ® [albutrepenonacog alfa, coagulation factor IX (recombinant), albumin fusion protein (rFIX-FP)], the innovative long-acting recombinant albumin fusion protein from CSL Behring for the treatment of hemophilia B 1. The regimen for routine prophylaxis has been up

Read more...

Two MedTech companies, Polaris Biology of China and Tetramer Shop of Denmark, announce a strategic partnership to co-develop and distribute technologies that accelerate T cell science. First on the agenda is to commercialize metal-labelled MHC tetramers for distribution in China. Conventional fluorophore labelled tetramers are restricted by spectral overlap and compensation issues. With quick, easy access to metal-labelled tetramers, researchers will be able to detect hundreds of T

Read more...